Cart
sales@molnova.com
Landipirdine
CAS No. 1000308-25-7
Landipirdine( RO-5025181 | SYN-120 )
Catalog No. M10003 CAS No. 1000308-25-7
A novel 5-HT receptor antagonist for the treatment of Parkinson's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 660 | Get Quote |
|
| 10MG | 888 | Get Quote |
|
| 25MG | 1377 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2520 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLandipirdine
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel 5-HT receptor antagonist for the treatment of Parkinson's disease.
-
DescriptionA novel 5-HT receptor antagonist for the treatment of Parkinson's disease.Parkinson's DiseasePhase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsRO-5025181 | SYN-120
-
PathwayGPCR/G Protein
-
Target5-HT Receptor
-
Recptor5-HT Receptor
-
Research AreaNeurological Disease
-
IndicationParkinson Disease
Chemical Information
-
CAS Number1000308-25-7
-
Formula Weight362.419
-
Molecular FormulaC18H19FN2O3S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(N)NC[C@@H]1CCCC2=C1C=CC(S(=O)(C3=CC=CC(F)=C3)=O)=C2
-
Chemical NameN-(((1R)-6-(3-fluorobenzenesulfonyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Huot P, et al. ACS Chem Neurosci. 2017 May 17;8(5):973-986.
molnova catalog
related products
-
Felcisetrag
Felcisetrag (TD-8954) is a potent and selective orally active 5-HT4 agonist with gastrointestinal prokinetic properties.
-
Glemanserin
Glemanserin (MDL11939) is a specific 5-HT2A antagonist with Ki values of 0.54 nM, 2.5 nM and 2.89 nM for rabbit, human and rat 5-HT2A.
-
L-694,247
L-694,247 is a selective 5-HT receptor agonist with affinity for 5-HT1D, 5-HT1A, 5-HT1B, 5-HT1C, and 5-HT1E receptors, and can be used to study neurological diseases.
